title: Analysis of the correlation between p53 and bcl-2 expression with staging and prognosis of the colorectal adenocarcinoma.
abstract: OBJECTIVE
  To analyze the correlation between p53 and bcl-2 expression and colorectal adenocarcinoma staging and prognosis.
  
  
  METHODS
  This was a retrospective series of 125 colorectal adenocarcinoma patients (67 women and 58 men; ages 30-87 years) who underwent surgery with curative intent. The mean follow-up was 28.5 months (range: 2-96 months). TNM staging, tumor recurrence, survival and cancer-related mortality were analyzed. Immunoreactivity was evaluated using DO7 (Dako) for p53 and K492 (Dako) for bcl-2. Tumors with accumulation of staining for cytoplasmic bcl-2 or nuclear p53 in more than 10% of cells were considered positive. Statistical analysis utilized Pearson chi-squared, log-rank and Wilcoxon tests, and Kaplan-Meier survival estimation (significance level: p<0.05).
  
  
  RESULTS
  p53+ was found in 11.8% (14/118), bcl-2+ in 50% (58/116) and associated p53+/bcl-2+ in 6.4% (7/109) of the tumors. There was no significant correlation between expression of these biomarkers and TNM I, II, III and IV staging (p=0.385 for p53; p=0.461 for bcl-2). For tumor recurrence, p53+ was found in 9.5% (2/21), bcl-2+ in 50% (11/22), and associated p53+/bcl-2+ in 5.2% (1/19) of the tumors (p=0.714, p=1.000 and p=0.960, respectively). For survival analysis, p53+: 57 months (45.0-68.0), bcl-2+: 78 (37.0-89.0), and p53+/bcl-2+: 62 (56.0-68.0) (p=0.319). For cancer-related mortality, p53+: 8.3% (3/36), bcl-2+: 47.2% (17/36), and p53+/bcl-2+: 5.9% (2/36) of the patients (p=0.432, p=0.688 and p=0.907, respectively).
  
  
  CONCLUSIONS
  No correlation was found between tumor expression of p53 and bcl-2 and the TNM staging, recurrence, survival and cancer-related mortality in colorectal adenocarcinoma.
authors.affiliation: UniFOA, Centro Universitário de Volta Redonda, Rio de Janeiro, Brazil.
authors.forename: Suzana Angelica Silva
authors.initials: SA
authors.lastname: Lustosa
authors.forename: Angela
authors.initials: A
authors.lastname: Logullo
authors.forename: Ricardo
authors.initials: R
authors.lastname: Artigiani
authors.forename: Sarhan Sydney
authors.initials: SS
authors.lastname: Saad
authors.forename: Alberto
authors.initials: A
authors.lastname: Goldenberg
authors.forename: Delcio
authors.initials: D
authors.lastname: Matos
mesh_terms: D000230:Adenocarcinoma / Q000401:mortality / Q000473:pathology*; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000032:analysis*; D001938:Brazil / Q000453:epidemiology; D015179:Colorectal Neoplasms / Q000401:mortality / Q000473:pathology*; D004812:Epidemiologic Methods; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000032:analysis*; D012008:Recurrence; D016159:Tumor Suppressor Protein p53 / Q000032:analysis*
chemical_list: D014408:Biomarkers, Tumor; D019253:Proto-Oncogene Proteins c-bcl-2; D016159:Tumor Suppressor Protein p53